Prognostic value of volumetric parameters of 18F-FDG PET in non-small-cell lung cancer: a meta-analysis

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 42, Issue 2, 2015, Pages 241-251

  Im, Hyung Jun ^a,b   Pak, Kyoungjune ^a,c   Cheon, Gi Jeong ^a   Kang, Keon Wook ^a   Kim, Seong Jang ^c   Kim, In Joo ^c   Chung, June Key ^a   Kim, E Edmund ^b,d   Lee, Dong Soo ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c Pusan National University Hospital   (South Korea)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Lung cancer; PET; Prognosis; Volume

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; DIAGNOSTIC USE; EVALUATION STUDY; EVENT FREE SURVIVAL; FEMALE; GLYCOLYSIS; HUMAN; LUNG TUMOR; MALE; META ANALYSIS; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; SCINTISCANNING; SYSTEMATIC REVIEW; TUMOR VOLUME; VOLUMETRY;

CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSTIC USE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS;

EID: 84964292600     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2903-7     Document Type: Article

References (58)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.
2. Zaizen Y, Azuma K, Kurata S, Sadashima E, Hattori S, Sasada T, et al. Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy. Eur J Radiol. 2012;81(12):4179–84.
3. Vu CC, Matthews R, Kim B, Franceschi D, Bilfinger TV, Moore WH. Prognostic value of metabolic tumor volume and total lesion glycolysis from (18)F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer. Nucl Med Commun. 2013;34(10):959–63.
4. Zarogoulidis K, Zarogoulidis P, Darwiche K, Boutsikou E, Machairiotis N, Tsakiridis K, et al. Treatment of non-small cell lung cancer (NSCLC). J Thorac Dis. 2013;5 Suppl 4:S389–S96.
5. 18F-FDG uptake in differentiating between metastatic and inflammatory lymph nodes in adenocarcinoma of the lung: comparison with other parameters and its application in a clinical setting. Nucl Med Mol Imaging. 2013;47(4):232–41.
6. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2(8):706–14.
7. Lee P, Weerasuriya DK, Lavori PW, Quon A, Hara W, Maxim PG, et al. Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys. 2007;69(2):328–33.
8. De Leyn P, Lardinois D, Van Schil PE, Rami-Porta R, Passlick B, Zielinski M, et al. ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer. Eur J Cardiothorac Surg. 2007;32(1):1–8.
9. Stroobants SG, D’Hoore I, Dooms C, De Leyn PR, Dupont PJ, De Wever W, et al. Additional value of whole-body fluorodeoxyglucose positron emission tomography in the detection of distant metastases of non-small-cell lung cancer. Clin Lung Cancer. 2003;4(4):242–7.
10. Paidpally V, Chirindel A, Lam S, Agrawal N, Quon H, Subramaniam RM. FDG-PET/CT imaging biomarkers in head and neck squamous cell carcinoma. Imaging Med. 2012;4(6):633–47.
11. Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, Castaigne C, et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol. 2008;3(1):6–12.
12. Paesmans M, Berghmans T, Dusart M, Garcia C, Hossein-Foucher C, Lafitte JJ, et al. Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. J Thorac Oncol. 2010;5(5):612–9.
13. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) AJCC cancer staging handbook. From the AJCC cancer staging manual, 7th ed. New York: Springer; 2010.
14. National Comprehensive Cancer Network. Non-Small Cell Lung Cancer (version 3.2014). http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed 13 March 2014.
15. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma. J Nucl Med. 2012;53(10):1506–13.
16. Hoang JK, Hoagland LF, Coleman RE, Coan AD, Herndon 2nd JE, Patz Jr EF. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. J Clin Oncol. 2008;26(9):1459–64.
17. Romesser PB, Qureshi MM, Shah BA, Chatburn LT, Jalisi S, Devaiah AK, et al. Superior prognostic utility of gross and metabolic tumor volume compared to standardized uptake value using PET/CT in head and neck squamous cell carcinoma patients treated with intensity-modulated radiotherapy. Ann Nucl Med. 2012;26(7):527–34.
18. Van de Wiele C, Kruse V, Smeets P, Sathekge M, Maes A. Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours. Eur J Nucl Med Mol Imaging. 2013;40(2):290–301.
19. Dewalle-Vignion AS, Yeni N, Petyt G, Verscheure L, Huglo D, Beron A, et al. Evaluation of PET volume segmentation methods: comparisons with expert manual delineations. Nucl Med Commun. 2012;33(1):34–42.
20. Moon SH, Hyun SH, Choi JY. Prognostic significance of volume-based PET parameters in cancer patients. Korean J Radiol. 2013;14(1):1–12.
21. 18F] fluoro-D-glucose with positron emission tomography in patients with esophageal cancer. Mol Imaging Biol. 2002;4(4):301–10.
22. Rahim MK, Kim SE, So H, Kim HJ, Cheon GJ, Lee ES, et al. Recent trends in PET image interpretations using volumetric and texture-based quantification methods in nuclear oncology. Nucl Med Mol Imaging. 2014;48(1):1–15
23. Chung HH, Kim JW, Han KH, Eo JS, Kang KW, Park NH, et al. Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer. Gynecol Oncol. 2011;120(2):270–4.
24. Hyun SH, Ahn HK, Kim H, Ahn MJ, Park K, Ahn YC, et al. Volume-based assessment by (18)F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):50–8.
25. Kim K, Kim SJ, Kim IJ, Kim YS, Pak K, Kim H. Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer. Nucl Med Commun. 2012;33(6):613–20.
26. Pan L, Gu P, Huang G, Xue H, Wu S. Prognostic significance of SUV on PET/CT in patients with esophageal cancer: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2009;21(9):1008–15.
27. Pak K, Cheon GJ, Nam HY, Kim SJ, Kang KW, Chung JK, et al. Prognostic value of metabolic tumor volume and total lesion glycolysis in head and neck cancer: a systematic review and meta-analysis. J Nucl Med. 2014;55(6):884–90.
28. Zhao Q, Feng Y, Mao X, Qie M. Prognostic value of fluorine-18-fluorodeoxyglucose positron emission tomography or PET-computed tomography in cervical cancer: a meta-analysis. Int J Gynecol Cancer. 2013;23(7):1184–90.
29. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–34.
30. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.
31. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.
32. Abelson JA, Murphy JD, Trakul N, Bazan JG, Maxim PG, Graves EE, et al. Metabolic imaging metrics correlate with survival in early stage lung cancer treated with stereotactic ablative radiotherapy. Lung Cancer. 2012;78(3):219–24.
33. Lin Y, Lin WY, Kao CH, Yen KY, Chen SW, Yeh JJ. Prognostic value of preoperative metabolic tumor volumes on PET-CT in predicting disease-free survival of patients with stage I non-small cell lung cancer. Anticancer Res. 2012;32(11):5087–91.
34. Yan H, Wang R, Zhao F, Zhu K, Jiang S, Zhao W, et al. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy. Acta Radiol. 2011;52(6):646–50.
35. Melloni G, Gajate AM, Sestini S, Gallivanone F, Bandiera A, Landoni C, et al. New positron emission tomography derived parameters as predictive factors for recurrence in resected stage I non-small cell lung cancer. Eur J Surg Oncol. 2013;39(11):1254–61.
36. Davison J, Mercier G, Russo G, Subramaniam RM. PET-based primary tumor volumetric parameters and survival of patients with non-small cell lung carcinoma. AJR Am J Roentgenol. 2013;200(3):635–40.
37. Hyun SH, Choi JY, Kim K, Kim J, Shim YM, Um SW, et al. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection. Ann Surg. 2013;257(2):364–70.
38. Yoo SW, Kim J, Chong A, Kwon SY, Min JJ, Song HC, et al. Metabolic tumor volume measured by F-18 FDG PET/CT can further stratify the prognosis of patients with stage IV non-small cell lung cancer. Nucl Med Mol Imaging. 2012;46(4):286–93.
39. Chen HH, Chiu NT, Su WC, Guo HR, Lee BF. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology. 2012;264(2):559–66.
40. Kim DH, Son SH, Kim CY, Hong CM, Oh JR, Song BI, et al. Prediction for recurrence using F-18 FDG PET/CT in pathologic N0 lung adenocarcinoma after curative surgery. Ann Surg Oncol. 2014:21(2):589–96.
41. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s – meta-analytic comparison of PET and CT. Radiology. 1999;213(2):530–6.
42. Gould MK, Kuschner WG, Rydzak CE, Maclean CC, Demas AN, Shigemitsu H, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med. 2003;139(11):879–92.
43. Birim O, Kappetein AP, Stijnen T, Bogers AJ. Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. Ann Thorac Surg. 2005;79(1):375–82.
44. Alongi F, Ragusa P, Montemaggi P, Bona CM. Combining independent studies of diagnostic fluorodeoxyglucose positron-emission tomography and computed tomography in mediastinal lymph node staging for non-small cell lung cancer. Tumori. 2006;92(4):327–33.
45. Lv YL, Yuan DM, Wang K, Miao XH, Qian Q, Wei SZ, et al. Diagnostic performance of integrated positron emission tomography/computed tomography for mediastinal lymph node staging in non-small cell lung cancer: a bivariate systematic review and meta-analysis. J Thorac Oncol. 2011;6(8):1350–8.
46. 18F-FDG PET/CT scan in non-small cell lung cancer: comparison of TB and non-TB endemic regions. Eur J Radiol. 2012;81(11):3518–23.
47. Wang J, Welch K, Wang L, Kong FM. Negative predictive value of positron emission tomography and computed tomography for stage T1-2N0 non-small-cell lung cancer: a meta-analysis. Clin Lung Cancer. 2012;13(2):81–9.
48. Wu LM, Xu JR, Gu HY, Hua J, Chen J, Zhang W, et al. Preoperative mediastinal and hilar nodal staging with diffusion-weighted magnetic resonance imaging and fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer: which is better? J Surg Res. 2012;178(1):304–14.
49. Zhao L, He ZY, Zhong XN, Cui ML. (18)FDG-PET/CT for detection of mediastinal nodal metastasis in non-small cell lung cancer: a meta-analysis. Surg Oncol. 2012;21(3):230–6.
50. Liu T, Xu JY, Xu W, Bai YR, Yan WL, Yang HL. Fluorine-18 deoxyglucose positron emission tomography, magnetic resonance imaging and bone scintigraphy for the diagnosis of bone metastases in patients with lung cancer: which one is the best? – a meta-analysis. Clin Oncol (R Coll Radiol). 2011;23(5):350–8.
51. Qu X, Huang X, Yan W, Wu L, Dai K. A meta-analysis of (18)FDG-PET-CT, (18)FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. Eur J Radiol. 2012;81(5):1007–15.
52. Chang MC, Chen JH, Liang JA, Lin CC, Yang KT, Cheng KY, et al. Meta-analysis: comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastasis in patients with lung cancer. Acad Radiol. 2012;19(3):349–57.
53. Xu G, Zhao L, He Z. Performance of whole-body PET/CT for the detection of distant malignancies in various cancers: a systematic review and meta-analysis. J Nucl Med. 2012;53(12):1847–54.
54. Wu Y, Li P, Zhang H, Shi Y, Wu H, Zhang J, et al. Diagnostic value of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients. Int J Cancer. 2013;132(2):E37–47.
55. 18FDG PET-CT for distant metastasis staging in lung cancer patients. Surg Oncol. 2013;22(3):151–5.
56. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA. 2001;285(7):914–24.
57. 18FDG-PET/CT versus single time point 18FDG-PET/CT for the differential diagnosis of pulmonary nodules: a meta-analysis. Acta Radiol. 2013;54(7):770–7.
58. 18F-FDG-PET evaluation of pathological tumour response to neoadjuvant therapy in patients with NSCLC. Nucl Med Commun. 2013;34(1):71–7.